Abstract
The absence of expression of the p16(INK4a) gene product is observed in virtually all mesothelioma tumors and cell lines, whereas wild-type pRB expression is maintained. We have examined the potential therapeutic role of re-expressing the p16(INK4a) gene product in mice with established human mesothelioma xenografts. Experiments using Adp16 treatments in mesothelioma xenografts demonstrated prolonged survival and potential cure following treatment with p16(INK4a)-based gene therapy. These results demonstrate that p16(INK4a) gene transfer may play a therapeutic role in the treatment of mesothelioma.
Original language | English |
---|---|
Pages (from-to) | 1421-1425 |
Number of pages | 5 |
Journal | Cancer gene therapy |
Volume | 7 |
Issue number | 11 |
DOIs | |
State | Published - 2000 |
Keywords
- Cell cycle
- Gene therapy
- Mesothelioma
- Tumor suppressor
- p16(INK4a)